Skip to main content
Signal8

Stoke Therapeutics, Inc. (STOK)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc.

NASDAQ:STOKHealthcare
Pre+0.11%$26.57
Close$26.54+1.80%AH$27.20-2.32%since
Mkt Cap$1.74B
Float54.4M
O/S65.41M
PM VOL1K sh
$ Vol≈$27K
RVOL15.51×
Inst Own-
SI18.9%
Dilution
Stoke Therapeutics, Inc. logoNASDAQ:STOKPre$26.57+0.11%
Historical Data
DateOpenHighLowCloseVolume
Nov 6, 202626.4926.7225.9626.541,162,631
Nov 5, 202627.5027.5025.9426.071,215,520
Nov 4, 202627.7527.7526.6027.451,209,959
Nov 3, 202626.8427.5226.6326.991,727,622
Nov 2, 202626.3227.0325.8026.481,404,405
Oct 30, 202626.0426.7125.7626.291,856,821
Oct 29, 202626.3927.0026.0326.351,879,619
Oct 28, 202625.6826.5225.5426.41781,360
Oct 27, 202625.4426.3525.2126.131,325,216
Oct 26, 202625.2225.5224.5225.462,083,447
Oct 23, 202625.5325.8324.8025.042,156,224
Oct 22, 202625.8826.7225.6425.701,346,399
Oct 21, 202626.8327.2225.3125.682,257,815
Oct 20, 202624.9527.2224.8426.612,458,619
Oct 19, 202624.4925.0224.1324.82711,015
Oct 16, 202624.5624.6123.6424.17880,149
Oct 15, 202623.5424.6223.4524.61818,176
Oct 14, 202622.4323.3622.0523.261,089,796
Oct 13, 202624.0524.0622.3022.50618,021
Oct 12, 202624.6524.6724.1024.15372,992
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
12
HOLD
3
SELL
0
TOTAL15
Insider Trades
InsiderTypeShares
Ticho Barry profile photoTicho BarrySale7.0K
Ticho Barry profile photoTicho BarrySale200
Allan Jonathan profile photoAllan JonathanSale627
Ticho Barry profile photoTicho BarrySale1.1K
Cumbo Alexander profile photoCumbo AlexanderGrant/Award39.7K
Ticho Barry profile photoTicho BarrySale1.6K
Shareholders
-
Institutionalⓘ
(197)
0.8%
Insiderⓘ
(8)
0.0%
5%+ Owners
(0)
-
Unattributed (incl. retail)ⓘ
Insider0.8%
Sources: 13F, Form 4, 13D/13GO/S: 65.4M · as of 30 Oct 2026 · SEC cover page
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies.

Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States.

The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy.

Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy.

The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.

Key Metrics
Market Cap$1.74B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership-

13F filers report 76.17M shares, more than the 65.41M outstanding, so no percentage is shown. 13F reports lag by a quarter and shares lent to short sellers can be counted twice.

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateJun 19, 2019
Shares Outstanding65.41M
Authorized Shares
Float54.40M
52-Week Range
$18.80$40.22
$26.54(36th percentile)
Volume
Average Daily Volume1.37M
1.16M today vs 1.37M avg(-15%)

30d Avg

1.37M

60d Avg

1.18M

90d Avg

1.05M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...